{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:35:23Z","timestamp":1778232923429,"version":"3.51.4"},"reference-count":202,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/01474"],"award-info":[{"award-number":["PI17\/01474"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00335"],"award-info":[{"award-number":["PI19\/00335"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2017-84283-R"],"award-info":[{"award-number":["SAF2017-84283-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Increasing life expectancy has led to an aging population, which has consequently increased the prevalence of dementia. Alzheimer's disease (AD), the most common form of dementia worldwide, is estimated to make up 50\u201380% of all cases. AD cases are expected to reach 131 million by 2050, and this increasing prevalence will critically burden economies and health systems in the next decades. There is currently no treatment that can stop or reverse disease progression. In addition, the late diagnosis of AD constitutes a major obstacle to effective disease management. Therefore, improved diagnostic tools and new treatments for AD are urgently needed. In this review, we investigate and describe both well-established and recently discovered AD biomarkers that could potentially be used to detect AD at early stages and allow the monitoring of disease progression. Proteins such as NfL, MMPs, p-tau217, YKL-40, SNAP-25, VCAM-1, and Ng \/ BACE are some of the most promising biomarkers because of their successful use as diagnostic tools. In addition, we explore the most recent molecular strategies for an AD therapeutic approach and nanomedicine-based technologies, used to both target drugs to the brain and serve as devices for tracking disease progression diagnostic biomarkers. State-of-the-art nanoparticles, such as polymeric, lipid, and metal-based, are being widely investigated for their potential to improve the effectiveness of both conventional drugs and novel compounds for treating AD. The most recent studies on these nanodevices are deeply explained and discussed in this review.<\/jats:p><jats:p><jats:bold>Graphic Abstract<\/jats:bold><\/jats:p>","DOI":"10.1186\/s12951-021-00864-x","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T12:05:32Z","timestamp":1619697932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer\u2019s disease: from current to future challenges"],"prefix":"10.1186","volume":"19","author":[{"given":"Amanda","family":"Cano","sequence":"first","affiliation":[]},{"given":"Patric","family":"Turowski","sequence":"additional","affiliation":[]},{"given":"Miren","family":"Ettcheto","sequence":"additional","affiliation":[]},{"given":"Jason Thomas","family":"Duskey","sequence":"additional","affiliation":[]},{"given":"Giovanni","family":"Tosi","sequence":"additional","affiliation":[]},{"given":"Elena","family":"S\u00e1nchez-L\u00f3pez","sequence":"additional","affiliation":[]},{"given":"Maria Luisa","family":"Garc\u00eda","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Camins","sequence":"additional","affiliation":[]},{"given":"Eliana B.","family":"Souto","sequence":"additional","affiliation":[]},{"given":"Agust\u00edn","family":"Ruiz","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Marqui\u00e9","sequence":"additional","affiliation":[]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"864_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","volume":"18","author":"E Nichols","year":"2019","unstructured":"Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global, regional, and national burden of Alzheimer \u2019 s disease and other dementias, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88\u2013106.","journal-title":"Lancet Neurol"},{"key":"864_CR2","unstructured":"Prince PM, Prince M, Prince M, Karagiannidou M, Prince M, Karagiannidou M, et al. World Alzheimer Report 2016 Improving healthcare for people living with dementia. 2016."},{"issue":"3","key":"864_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/acn3.166","volume":"2","author":"JL Cummings","year":"2015","unstructured":"Cummings JL, Isaacson RS, Schmitt FA, Velting DM. A practical algorithm for managing Alzheimer\u2019 s disease: what, when, and why\u202f? Ann Clin Transl Neurol. 2015;2(3):307\u201323.","journal-title":"Ann Clin Transl Neurol"},{"key":"864_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","volume":"76","author":"R Anand","year":"2014","unstructured":"Anand R, Dip K, Ali A. Therapeutics of Alzheimer\u2019 s disease\u202f: past, present and future. Neuropharmacology. 2014;76:27\u201350.","journal-title":"Neuropharmacology"},{"issue":"2","key":"864_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ncl.2017.01.005","volume":"35","author":"MF Mendez","year":"2017","unstructured":"Mendez MF, Program BN, Greater VA, Angeles L. Early-onset Alzheimer\u2019s disease. Neurol Clin. 2017;35(2):263\u201381.","journal-title":"Neurol Clin"},{"key":"864_CR6","doi-asserted-by":"publisher","first-page":"201.e9","DOI":"10.1016\/j.neurobiolaging.2019.01.015","volume":"86","author":"T Hang","year":"2020","unstructured":"Hang T, Seelaar H, Melhem S, Rozemuller AJM, Van Swieten JC. Genetic screening in early-onset Alzheimer\u2019 s disease identified three novel presenilin mutations. Neurobiol Aging. 2020;86:201.e9-201.e14.","journal-title":"Neurobiol Aging."},{"key":"864_CR7","doi-asserted-by":"publisher","first-page":"104255","DOI":"10.1016\/j.phrs.2019.104255","volume":"145","author":"M Ettcheto","year":"2019","unstructured":"Ettcheto M, Cano A, Busquets O, Manzine P, S\u00e1nchez-L\u00f3pez E, Castro-Torres R, et al. A metabolic perspective of late onset Alzheimer \u2019 s disease. Pharmacol Res. 2019;145:104255.","journal-title":"Pharmacol Res."},{"key":"864_CR8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","volume":"25","author":"DA Nation","year":"2019","unstructured":"Nation DA, Sweeney MD, Montagne A, Sagare AP, D\u2019Orazio LM, Maricarmen P, Sepehrband F. Blood\u2013brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25:270\u20136.","journal-title":"Nat Med"},{"key":"864_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/cells9030600","volume":"9","author":"E Nutma","year":"2020","unstructured":"Nutma E, Amor S, Peferoen LAN. Astrocyte and oligodendrocyte cross-talk in the central nervous system. Cells. 2020;9:600.","journal-title":"Cells"},{"key":"864_CR10","doi-asserted-by":"crossref","first-page":"e12050","DOI":"10.1002\/trc2.12050","volume":"6","author":"J Cummings","year":"2020","unstructured":"Cummings J, Zhong K, Lee G, Ritter A, Sabbagh M. Alzheimer\u2019 s disease drug development pipeline: 2020. Alzheimer\u2019s Dement. 2020;6:e12050.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"2","key":"864_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2217\/nnm-2019-0367","volume":"5","author":"JJ Mulvihill","year":"2020","unstructured":"Mulvihill JJ, Cunnane EM, Ross AM, Duskey JT, Tosi G, Grabrucker AM. Drug delivery across the blood\u2013brain barrier: recent advances in the use of nanocarriers. Nanomedicine (London). 2020;5(2):205\u201314.","journal-title":"Nanomedicine (London)"},{"key":"864_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.irn.2017.08.006","volume":"137","author":"J Duskey","year":"2017","unstructured":"Duskey J, Belletti D, Pederzoli F, Vandelli M, Forni F, Ruozi B, et al. Current strategies for the delivery of therapeutic proteins and enzymes to treat brain disorders. Int Rev Neurobiol. 2017;137:1\u201328.","journal-title":"Int Rev Neurobiol."},{"issue":"5","key":"864_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1734-1140(12)70901-5","volume":"64","author":"AZ Wilczewska","year":"2012","unstructured":"Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64(5):1020\u201337.","journal-title":"Pharmacol Rep"},{"key":"864_CR14","doi-asserted-by":"publisher","first-page":"102226","DOI":"10.1016\/j.nano.2020.102226","volume":"28","author":"JT Duskey","year":"2020","unstructured":"Duskey JT, Ottonelli I, Da Ros F, Vilella A, Zoli M, Kovachka S, et al. Novel peptide-conjugated nanomedicines for brain targeting: in vivo evidence. Nanomed Nanotechnol Biol Med. 2020;28:102226.","journal-title":"Nanomed Nanotechnol Biol Med."},{"issue":"1","key":"864_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","volume":"5","author":"H Hippius","year":"2003","unstructured":"Hippius H. The discovery of Alzheimer\u2019s disease. Dialogues Clin Neurosci. 2003;5(1):101\u20138.","journal-title":"Dialogues Clin Neurosci"},{"issue":"11","key":"864_CR16","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","volume":"9","author":"B Dubois","year":"2010","unstructured":"Dubois B, Feldman HH, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G. Revising the definition of Alzheimer\u2019s disease: a new lexicon. Lancet Neurol. 2010;9(11):1118\u201327.","journal-title":"Lancet Neurol."},{"issue":"1","key":"864_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-020-00594-6","volume":"12","author":"M Alegret","year":"2020","unstructured":"Alegret M, Mu\u00f1oz N, Roberto N, Rentz DM, Valero S, Gil S, et al. A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory\u00ae) for the early detection of Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12(1):25.","journal-title":"Alzheimers Res Ther"},{"key":"864_CR18","doi-asserted-by":"publisher","first-page":"100005","DOI":"10.1016\/j.bionps.2019.100005","volume":"1","author":"R Khoury","year":"2019","unstructured":"Khoury R, Ghossoub E. Diagnostic biomarkers of Alzheimer\u2019s disease: a state-of-the-art review. Biomark Neuropsychiatr. 2019;1:100005.","journal-title":"Biomark Neuropsychiatr"},{"issue":"4","key":"864_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein S, Holtzman DM, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement."},{"key":"864_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.neuroscience.2017.07.017","volume":"370","author":"KN El","year":"2018","unstructured":"El KN, Said N, Slassi I, Moutawakil E, Nadifi S. Biomarkers for Alzheimer Disease: classical and novel candidates \u2019 review. Neuroscience. 2018;370:181\u201390.","journal-title":"Neuroscience"},{"key":"864_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fnagi.2019.00282","volume":"11","author":"M Canevelli","year":"2019","unstructured":"Canevelli M, Bacigalupo I, Gervasi G, Lacorte E, Massari M, Mayer F, et al. Methodological Issues in the clinical validation of biomarkers for Alzheimer\u2019 s Disease: the paradigmatic example of CSF. Front Aging Neurosci. 2019;11:282.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"864_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.clinph.2020.03.003","volume":"131","author":"PM Rossini","year":"2020","unstructured":"Rossini PM, Iorio RD, Vecchio F, Anfossi M, Babiloni C, Bozzali M, et al. Early diagnosis of Alzheimer\u2019 s disease\u202f: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts. Cli Neurophysiol. 2020;131(6):1287\u2013310.","journal-title":"Cli Neurophysiol."},{"issue":"1","key":"864_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","volume":"11","author":"K Blennow","year":"2015","unstructured":"Blennow K, Dubois B, Fagan A, Lewczuk P, de Leon M, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease. Alzheimer\u2019s Dementia. 2015;11(1):58\u201369.","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"1","key":"864_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40478-019-0795-2","volume":"7","author":"CD Whelan","year":"2019","unstructured":"Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S, et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer \u2019 s disease. Acta Neuropathol Commun. 2019;7(1):169.","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"864_CR25","doi-asserted-by":"publisher","first-page":"e0193707","DOI":"10.1371\/journal.pone.0193707","volume":"13","author":"BA Trombetta","year":"2018","unstructured":"Trombetta BA, Carlyle BC, Koenig AM, Shaw LM, Trojanowski Q, Wolk DA, et al. The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer\u2019 s disease. PLoS ONE. 2018;13(3):e0193707.","journal-title":"PLoS ONE"},{"issue":"7","key":"864_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"key":"864_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s12276-020-0418-9","volume":"52","author":"SA Park","year":"2020","unstructured":"Park SA, Han S, Kim CE. New fluid biomarkers tracking non-amyloid- \u03b2 and non-tau pathology in Alzheimer \u2019 s disease. Exp Mol Med. 2020;52:556\u201368.","journal-title":"Exp Mol Med"},{"key":"864_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jns.2016.01.008","volume":"361","author":"M Awasthi","year":"2016","unstructured":"Awasthi M, Singh S, Pandey VP, Dwivedi UN. Alzheimer \u00e2\u20acTM s disease: an overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. J Neurol Sci. 2016;361:256\u201371.","journal-title":"J Neurol Sci"},{"key":"864_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286419888819","volume":"12","author":"M Mil\u00e0-Alom\u00e0","year":"2019","unstructured":"Mil\u00e0-Alom\u00e0 M, Su\u00e1rez-calvet M, Molinuevo JL. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer \u2019 s disease. Ther Adv Neurol Disord. 2019;12:1\u201323.","journal-title":"Ther Adv Neurol Disord"},{"key":"864_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clinbiochem.2019.04.002","volume":"72","author":"K Hrube\u0161ov\u00e1","year":"2019","unstructured":"Hrube\u0161ov\u00e1 K, Fouskov\u00e1 M, Habartov\u00e1 L, Fi\u0161ar Z, Jir\u00e1k R. Search for biomarkers of Alzheimer \u2018 s disease: recent insights, current challenges and future prospects. Clin Biochem. 2019;72:39\u201351.","journal-title":"Clin Biochem"},{"issue":"2","key":"864_CR31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s Disease. J Alzheimers Dis. 2017;55(2):813\u201322.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"864_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3(3):154\u201365.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"864_CR33","first-page":"34","volume":"6","author":"V P\u00e9rez-Grijalba","year":"2019","unstructured":"P\u00e9rez-Grijalba V, Romero J, Pesini P, Sarasa L, Monle\u00f3n I, San-Jos\u00e9 I, et al. Plasma A\u03b242\/40 ratio detects early stages of Alzheimer\u2019s disease and correlates with CSF and neuroimaging biomarkers in the AB255 study. J Prev Alzheimers Dis. 2019;6(1):34\u201341.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"864_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13195-019-0549-1","volume":"11","author":"V P\u00e9rez-Grijalba","year":"2019","unstructured":"P\u00e9rez-Grijalba V, Arbizu J, Romero J, Prieto E, Pesini P, Sarasa L, et al. Plasma A\u03b242\/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Alzheimers Res Ther. 2019;11(1):96.","journal-title":"Alzheimers Res Ther"},{"key":"864_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jneumeth.2018.10.025","volume":"319","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H. Blood-based biomarkers for Alzheimer \u2019 s disease\u2014an update. J Neurosci Methods. 2019;319:2\u20136.","journal-title":"J Neurosci Methods"},{"key":"864_CR36","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fneur.2017.00102","volume":"8","author":"RA Huynh","year":"2017","unstructured":"Huynh RA, Mohan C, Huynh RA, Mohan C. Alzheimer\u2019s Disease: biomarkers in the genome, blood, and cerebrospinal fluid. Front Neurol. 2017;8:102.","journal-title":"Front Neurol"},{"issue":"1","key":"864_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/JAD-151029","volume":"53","author":"J Schuster","year":"2016","unstructured":"Schuster J, Funke SA. Methods for the specific detection and quantitation of amyloid-\u03b2 oligomers in cerebrospinal fluid. J Alzheimers Dis. 2016;53(1):53\u201367.","journal-title":"J Alzheimers Dis"},{"key":"864_CR38","unstructured":"Alzforum. Plasma A\u03b2 test wins approval\u2014are p-tau tests far behind?. 2020. https:\/\/www.alzforum.org\/news\/research-news\/plasma-av-test-wins-approval-are-p-tau-tests-far-behind."},{"key":"864_CR39","doi-asserted-by":"crossref","unstructured":"Hampel H, Vassar R, De Strooper B, Hardy J, Willem M, Singh N, et al. The \u03b2-Secretase BACE1 in Alzheimer\u2019s Disease. Biological Psychiatry. 2020;In press.","DOI":"10.1016\/j.biopsych.2020.02.001"},{"issue":"1","key":"864_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3233\/JAD-2010-1367","volume":"20","author":"SD Mulder","year":"2010","unstructured":"Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, et al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis. 2010;20(1):253\u201360.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"864_CR41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3233\/JAD-2011-091153","volume":"25","author":"M Ewers","year":"2011","unstructured":"Ewers M, Cheng X, Zhong Z, Nural HF, Walsh C, Meindl T, et al. Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer\u2019s disease. J Alzheimers Dis. 2011;25(2):373\u201381.","journal-title":"J Alzheimers Dis"},{"key":"864_CR42","doi-asserted-by":"publisher","first-page":"S425","DOI":"10.1016\/j.jalz.2013.09.006","volume":"10","author":"R Perneczky","year":"2014","unstructured":"Perneczky R, Alexopoulos P. Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer\u2019s disease. Alzheimers Dement. 2014;10:S425-S429.e1.","journal-title":"Alzheimers Dement."},{"issue":"2","key":"864_CR43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3233\/JAD-142778","volume":"46","author":"MJ Savage","year":"2015","unstructured":"Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ. Soluble BACE-1 activity and sA\u03b2PP\u03b2 Concentrations in Alzheimer\u2019s Disease and age-matched healthy control cerebrospinal fluid from the Alzheimer\u2019s Disease neuroimaging initiative-1 baseline cohort. J Alzheimers Dis. 2015;46(2):431\u201340.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"864_CR44","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.biopsych.2017.02.007","volume":"83","author":"Y Shen","year":"2018","unstructured":"Shen Y, Wang H, Sun Q, Yao H, Keegan AP, Mullan M, et al. Increased plasma BACE1 may predict conversion to Alzheimer\u2019s Disease dementia in individuals with mild cognitive impairment. Biol Psychiatry. 2018;83(5):447\u201355.","journal-title":"Biol Psychiatry"},{"issue":"13","key":"864_CR45","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Tung Y, Quinlan M, Wisniewski H, Binder L. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83(13):4913\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"864_CR46","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","volume":"126","author":"T Arendt","year":"2016","unstructured":"Arendt T, Stieler JT, Holzer M. Tau and tauopathies. Brain Res Bull. 2016;126:238\u201392.","journal-title":"Brain Res Bull"},{"key":"864_CR47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.mcn.2018.12.001","volume":"97","author":"M Sch\u00f6ll","year":"2019","unstructured":"Sch\u00f6ll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, et al. Biomarkers for tau pathology. Mol Cell Neurosci. 2019;97:18\u201333.","journal-title":"Mol Cell Neurosci"},{"key":"864_CR48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12883-019-1591-0","volume":"20","author":"C Wattmo","year":"2020","unstructured":"Wattmo C, Blennow K, Hansson O. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer\u2019s disease. BMC Neurol. 2020;20:10.","journal-title":"BMC Neurol"},{"issue":"9","key":"864_CR49","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1212\/WNL.0000000000006075","volume":"91","author":"AJ Aschenbrenner","year":"2018","unstructured":"Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassensta JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology. 2018;91(9):e859\u201366.","journal-title":"Neurology"},{"issue":"6","key":"864_CR50","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jalz.2019.01.015","volume":"151","author":"A Lle\u00f3","year":"2019","unstructured":"Lle\u00f3 A, Alcolea D, Mart\u00ednez-Lage P, Scheltens P, Parnetti L, Poirier J, et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer\u2019s disease continuum in the BIOMARKAPD study. Alzheimers Dement. 2019;151(6):742\u201353.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"864_CR51","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989\u201397.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"864_CR52","doi-asserted-by":"publisher","first-page":"e0159099","DOI":"10.1371\/journal.pone.0159099","volume":"11","author":"S Shekhar","year":"2016","unstructured":"Shekhar S, Kumar R, Rai N, Kumar V, Singh K, Upadhyay AD, et al. Estimation of tau and phosphorylated tau181 in serum of Alzheimer\u2019s Disease and mild cognitive impairment patients. PLoS ONE. 2016;11(7):e0159099.","journal-title":"PLoS ONE"},{"issue":"4","key":"864_CR53","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3233\/JAD-170810","volume":"61","author":"C-C Yang","year":"2018","unstructured":"Yang C-C, Chiu M-J, Chen T-F, Chang H-L, Liu B-H, Yang S-Y. Assay of plasma phosphorylated tau protein (Threonine 181) and total tau protein in early-stage Alzheimer\u2019s Disease. J Alzheimers Dis. 2018;61(4):1323\u201332.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"864_CR54","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer Disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381.","journal-title":"JAMA"},{"issue":"11","key":"864_CR55","doi-asserted-by":"publisher","first-page":"e20200861","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med. 2020;217(11):e20200861.","journal-title":"J Exp Med"},{"key":"864_CR56","doi-asserted-by":"crossref","first-page":"e12921","DOI":"10.15252\/emmm.202012921","volume":"10","author":"M Su\u00e1rez-Calvet","year":"2020","unstructured":"Su\u00e1rez-Calvet M, Karikari T, Ashton N, Lantero Rodr\u00edguez J, Mil\u00e0-Alom\u00e0 M, Gispert J, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected. EMBO Mol Med. 2020;10:e12921.","journal-title":"EMBO Mol Med"},{"key":"864_CR57","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"17","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson A, Strandberg O, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain. 2020;17:3234.","journal-title":"Brain"},{"issue":"5","key":"864_CR58","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jalz.2019.01.004","volume":"15","author":"I Bos","year":"2019","unstructured":"Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, Sleegers K. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer\u2019s disease spectrum. Alzheimers Dement. 2019;15(5):644\u201354.","journal-title":"Alzheimers Dement."},{"issue":"21","key":"864_CR59","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","volume":"83","author":"T Skillb\u00e4ck","year":"2014","unstructured":"Skillb\u00e4ck T, Farahmand B, Bartlett JW, Ros\u00e9n C, Mattsson N, N\u00e4gga K, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014;83(21):1945\u201353.","journal-title":"Neurology"},{"issue":"7","key":"864_CR60","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer Disease. JAMA Neurol. 2019;76(7):791\u20139.","journal-title":"JAMA Neurol"},{"issue":"1","key":"864_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-019-0472-5","volume":"11","author":"PSJ Weston","year":"2019","unstructured":"Weston PSJ, Poole T, O\u2019Connor A, Heslegrave A, Ryan NS, Liang Y, et al. Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11(1):19.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"864_CR62","first-page":"e12099","volume":"12","author":"LL Raket","year":"2020","unstructured":"Raket LL, K\u00fchnel L, Schmidt E, Blennow K, Zetterberg H, Mattsson-Carlgren N. Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer\u2019s disease. Alzheimers Dement (Amst). 2020;12(1):e12099.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"864_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/JAD-150060","volume":"47","author":"M Groblewska","year":"2015","unstructured":"Groblewska M, Muszy\u0144ski P, Wojtulewska-Supron A, Kulczy\u0144ska-Przybik A, Mroczko B. The role of visinin-like protein-1 in the pathophysiology of Alzheimer\u2019s Disease. J Alzheimers Dis. 2015;47(1):17\u201332.","journal-title":"J Alzheimers Dis"},{"key":"864_CR64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40035-018-0127-7","volume":"7","author":"H Zhang","year":"2018","unstructured":"Zhang H, Pin Ng K, Therriault J, Kang MS, Pascoal TA, Rosa-Neto P, et al. Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer\u2019s disease. Transl Neurodegener. 2018;7:23.","journal-title":"Transl Neurodegener"},{"issue":"11","key":"864_CR65","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.2174\/1567205014666170203141717","volume":"14","author":"F Regen","year":"2017","unstructured":"Regen F, Hellmann-Regen J, Costantini E, Reale M. Neuroinflammation and Alzheimer\u2019s Disease: implications for microglial activation. Curr Alzheimer Res. 2017;14(11):1140\u2013448.","journal-title":"Curr Alzheimer Res"},{"issue":"6","key":"864_CR66","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P. Neuroinflammation in Alzheimer \u2019 s disease: current evidence and future directions. Alzheimer\u2019s Dementia. 2016;12(6):719\u201332.","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"737846","key":"864_CR67","first-page":"1","volume":"2012","author":"T Mizuno","year":"2012","unstructured":"Mizuno T. The biphasic role of microglia in Alzheimer\u2019 s disease. Int J Alzheimer\u2019s Dis. 2012;2012(737846):1\u20139.","journal-title":"Int J Alzheimer\u2019s Dis"},{"issue":"4","key":"864_CR68","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.biopsych.2017.10.007","volume":"83","author":"C Condello","year":"2018","unstructured":"Condello C, Yuan P, Grutzendler J. Microglia-mediated neuroprotection, TREM2, and Alzheimer\u2019s Disease: evidence from optical imaging. Biol Psychiat. 2018;83(4):377\u201387.","journal-title":"Biol Psychiat"},{"issue":"3","key":"864_CR69","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jnr.1242","volume":"66","author":"M Sj\u00f6gren","year":"2001","unstructured":"Sj\u00f6gren M, Blomberg M, Jonsson M, Wahlund L, Edman A, Lind K, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res. 2001;66(3):510\u20136.","journal-title":"J Neurosci Res"},{"issue":"3","key":"864_CR70","first-page":"1","volume":"12","author":"P Parbo","year":"2020","unstructured":"Parbo P, Madsen LS, Ismail R, Zetterberg H, Blennow K, Eskildsen SF, et al. Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer \u2019 s disease. Alzheimer\u2019s Res Therapy. 2020;12(3):1\u20137.","journal-title":"Alzheimer\u2019s Res Therapy"},{"key":"864_CR71","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","volume":"11","author":"M Khalil","year":"2020","unstructured":"Khalil M, Pirpamer L, Hofer E, Voortman MM, Barro C, Leppert D, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. 2020;11:812. https:\/\/doi.org\/10.1038\/s41467-020-14612-6.","journal-title":"Nat Commun"},{"issue":"4","key":"864_CR72","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/14789450.2017.1304217","volume":"14","author":"F Baldacci","year":"2017","unstructured":"Baldacci F, Lista S, Cavedo E, Bonuccelli U, Hampel H. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer\u2019s disease and other neurodegenerative diseases. Expert Rev Proteomics. 2017;14(4):285\u201399.","journal-title":"Expert Rev Proteomics"},{"issue":"3","key":"864_CR73","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3390\/cells8030230","volume":"8","author":"A Mendsaikhan","year":"2019","unstructured":"Mendsaikhan A, Tooyama I, Walker DG. Microglial progranulin: involvement in Alzheimer\u2019s Disease and neurodegenerative diseases. Cells. 2019;8(3):230.","journal-title":"Cells"},{"issue":"7","key":"864_CR74","first-page":"1","volume":"4","author":"Z Ahmed","year":"2007","unstructured":"Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation. 2007;4(7):1\u201313.","journal-title":"J Neuroinflammation"},{"issue":"12","key":"864_CR75","doi-asserted-by":"publisher","first-page":"e9712","DOI":"10.15252\/emmm.201809712","volume":"10","author":"M Su\u00e1rez-Calvet","year":"2018","unstructured":"Su\u00e1rez-Calvet M, Capell A, Araque Caballero M\u00c1, Morenas-Rodr\u00edguez E, Fellerer K, Franzmeier N, et al. CSF progranulin increases in the course of Alzheimer\u2019s disease and is associated with sTREM2, neurodegeneration and cognitive decline. EMBO Mol Med. 2018;10(12):e9712.","journal-title":"EMBO Mol Med"},{"issue":"6","key":"864_CR76","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2174\/1567205013666160314151247","volume":"13","author":"C Wilke","year":"2016","unstructured":"Wilke C, Gillardon F, Deuschle C, Dubois E, Hobert MA, vom Hagen MJ, et al. Serum levels of progranulin do not reflect cerebrospinal fluid levels in neurodegenerative disease. Curr Alzheimer Res. 2016;13(6):654\u201362.","journal-title":"Curr Alzheimer Res."},{"key":"864_CR77","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fnagi.2018.00202","volume":"10","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Ulland TK, Colonna M. TREM2-dependent effects on microglia in Alzheimer\u2019s Disease. Front Aging Neurosci. 2018;10:202.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"864_CR78","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med. 2013;368(2):107\u201316.","journal-title":"N Engl J Med"},{"key":"864_CR79","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12974-020-01853-x","volume":"17","author":"S Chen","year":"2020","unstructured":"Chen S, Peng J, Sherchan P, Ma Y, Xiang S, Yan F, et al. TREM2 activation attenuates neuroinflammation and neuronal apoptosis via PI3K\/Akt pathway after intracerebral hemorrhage in mice. J Neuroinflammation. 2020;17:168.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"864_CR80","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41467-019-09118-9","volume":"10","author":"L Zhong","year":"2019","unstructured":"Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer\u2019s disease model. Nat Commun. 2019;10(1):1365.","journal-title":"Nat Commun"},{"issue":"9","key":"864_CR81","doi-asserted-by":"publisher","first-page":"e12308","DOI":"10.15252\/emmm.202012308","volume":"12","author":"M Ewers","year":"2020","unstructured":"Ewers M, Biechele G, Su\u00e1rez-Calvet M, Sacher C, Blume T, Morenas-Rodriguez E, et al. Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. EMBO Mol Med. 2020;12(9):e12308.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"864_CR82","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14737175.2016.1204234","volume":"17","author":"S Lista","year":"2017","unstructured":"Lista S, Hampel H. Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer\u2019s disease. Expert Rev Neurother. 2017;17(1):47\u201357.","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"864_CR83","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.bcp.2014.01.015","volume":"88","author":"CR Overk","year":"2014","unstructured":"Overk CR, Masliah E. Pathogenesis of synaptic degeneration in Alzheimer\u2019s disease and Lewy Body disease. Biochem Pharmacol. 2014;88(4):508\u201316.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"864_CR84","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0169-328X(95)00257-S","volume":"36","author":"JE Cheetham","year":"1996","unstructured":"Cheetham JE, Martzen MR, Kazee AM, Coleman PD. Gap-43 message levels in anterior cerebellum in Alzheimer\u2019s disease. Brain Res Mol Brain Res. 1996;36(1):145\u201351.","journal-title":"Brain Res Mol Brain Res"},{"issue":"1","key":"864_CR85","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","volume":"15","author":"\u00c5 Sandelius","year":"2019","unstructured":"Sandelius \u00c5, Portelius E, K\u00e4ll\u00e9n \u00c5, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with tau and amyloid pathology. Alzheimers Dement. 2019;15(1):55\u201364.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"864_CR86","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-018-0407-6","volume":"10","author":"H Zhang","year":"2018","unstructured":"Zhang H, Therriault J, Kang MS, Pin Ng K, Pascoal TA, Rosa-Neto P, et al. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10(1):80.","journal-title":"Alzheimers Res Ther"},{"key":"864_CR87","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neulet.2018.08.029","volume":"685","author":"S Wang","year":"2018","unstructured":"Wang S, Zhang J, Pan T. APOE \u03b54 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer\u2019s disease. Neurosci Lett. 2018;685:109\u201313.","journal-title":"Neurosci Lett"},{"issue":"8","key":"864_CR88","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1007\/s12035-019-1501-x","volume":"56","author":"C Agliardi","year":"2019","unstructured":"Agliardi C, Guerini FR, Zanzottera M, Bianchi A, Nemni R, Clerici M. SNAP-25 in serum is carried by exosomes of neuronal origin and is a potential biomarker of Alzheimer\u2019s Disease. Mol Neurobiol. 2019;56(8):5792\u20138.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"864_CR89","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF02815094","volume":"27","author":"P Davidsson","year":"1996","unstructured":"Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K. Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease? Mol Chem Neuropathol. 1996;27(2):195\u2013210.","journal-title":"Mol Chem Neuropathol"},{"issue":"1","key":"864_CR90","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13195-016-0208-8","volume":"8","author":"A \u00d6hrfelt","year":"2016","unstructured":"\u00d6hrfelt A, Brinkmalm A, Dumurgier J, Brinkmalm G, Hansson O, Zetterberg H, et al. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8(1):41.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"864_CR91","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh R, D\u2019Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, et al. Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer Disease. JAMA Neurol. 2016;73(5):561\u201371.","journal-title":"JAMA Neurol"},{"issue":"10","key":"864_CR92","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00018-019-03040-5","volume":"76","author":"K Dhiman","year":"2019","unstructured":"Dhiman K, Blennow K, Zetterberg H, Martins RN, Gupta VB. Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer\u2019s disease pathogenesis. Cell Mol Life Sci. 2019;76(10):1833\u201363.","journal-title":"Cell Mol Life Sci"},{"key":"864_CR93","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.trci.2018.10.003","volume":"4","author":"B-E Kirsebom","year":"2018","unstructured":"Kirsebom B-E, Nordengen K, Selnes P, Waterloo K, B\u00f8en Torsetnes S, G\u00edslad\u00f3ttir B, et al. Cerebrospinal fluid neurogranin\/\u03b2-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2018;4:617\u201327.","journal-title":"Alzheimers Dement (N Y)"},{"key":"864_CR94","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.nbd.2015.08.014","volume":"82","author":"LY Di Marco","year":"2015","unstructured":"Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF. Vascular dysfunction in the pathogenesis of Alzheimer\u2019s disease\u2013a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis. 2015;82:593\u2013606.","journal-title":"Neurobiol Dis."},{"issue":"5","key":"864_CR95","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/00365517709091496","volume":"37","author":"G Tibbling","year":"1997","unstructured":"Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest. 1997;37(5):385\u201390.","journal-title":"Scand J Clin Lab Invest."},{"issue":"7","key":"864_CR96","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jalz.2017.01.008","volume":"13","author":"MW Wong","year":"2017","unstructured":"Wong MW, Braidy N, Poljak A, Pickford R, Thambisetty M, Sachdev PS. Dysregulation of lipids in Alzheimer\u2019s disease and their role as potential biomarkers. Alzheimers Dement. 2017;13(7):810\u201327.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"864_CR97","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","volume":"101","author":"ME Belloy","year":"2019","unstructured":"Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer\u2019s Disease: progress to date and the path forward. Neuron. 2019;101(5):820\u201338.","journal-title":"Neuron"},{"key":"864_CR98","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fnagi.2016.00160","volume":"8","author":"M Ries","year":"2016","unstructured":"Ries M, Sastre M. Mechanisms of A\u03b2 clearance and degradation by glial cells. Front Aging Neurosci. 2016;8:160.","journal-title":"Front Aging Neurosci"},{"key":"864_CR99","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-015-0059-y","volume":"10","author":"WE Heywood","year":"2015","unstructured":"Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener. 2015;10:64.","journal-title":"Mol Neurodegener"},{"issue":"10","key":"864_CR100","first-page":"1","volume":"9","author":"L Wang","year":"2020","unstructured":"Wang L, Yin Y, Liu X, Shen P, Zheng Y, Lan X, et al. Current understanding of metal ions in the pathogenesis of Alzheimer \u2019 s disease. Transl Neurodegen. 2020;9(10):1\u201313.","journal-title":"Transl Neurodegen"},{"issue":"2","key":"864_CR101","first-page":"1","volume":"1","author":"S Wang","year":"2016","unstructured":"Wang S, Mims PN, Roman RJ, Fan F. Is beta-amyloid accumulation a cause or consequence of Alzheimer\u2019s Disease? J Alzheimers Parkinsonism Dement. 2016;1(2):1\u20138.","journal-title":"J Alzheimers Parkinsonism Dement"},{"issue":"9770","key":"864_CR102","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","volume":"377","author":"C Ballard","year":"2011","unstructured":"Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer \u2019 s disease. Lancet. 2011;377(9770):1019\u201331.","journal-title":"Lancet"},{"key":"864_CR103","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.3390\/ijms19071884","volume":"19","author":"B Mroczko","year":"2018","unstructured":"Mroczko B, Groblewska M, Litman-zawadzka A, Kornhuber J, Lewczuk P. Cellular receptors of amyloid \u03b2 oligomers (A\u03b2Os) in Alzheimer\u2019s Disease. Int J Mol Sci. 2018;19:1884.","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"864_CR104","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ijpharm.2010.01.012","volume":"389","author":"A Smith","year":"2010","unstructured":"Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD. Nanolipidic particles improve the bioavailability and \u03b1 -secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer\u2019 s disease. Int J Pharm. 2010;389(1\u20132):207\u201312.","journal-title":"Int J Pharm"},{"key":"864_CR105","unstructured":"de la Torre R. Prevention of cognitive decline in ApoE4 Carriers with subjective cognitive decline after EGCG and a multimodal intervention ((PENSA)). ClinicalTrials.gov. 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03978052."},{"key":"864_CR106","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1471-4159.2008.05396.x","volume":"106","author":"M Marcade","year":"2008","unstructured":"Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochemistry. 2008;106:392\u2013404.","journal-title":"J Neurochemistry"},{"key":"864_CR107","doi-asserted-by":"publisher","first-page":"20002","DOI":"10.1063\/1.5085515","volume":"2058","author":"Z Li","year":"2019","unstructured":"Li Z. New APOE-related therapeutic options for Alzheimer \u2019 s disease. AIP Conf Proc. 2019;2058:20002.","journal-title":"AIP Conf Proc"},{"key":"864_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2014.00093","volume":"6","author":"T Kanekiyo","year":"2014","unstructured":"Kanekiyo T, Bu G. The low-density lipoprotein receptor-related protein 1 and amyloid- \u03b2 clearance in Alzheimer\u2019 s disease. Front Aging Neurosci. 2014;6:1\u201312.","journal-title":"Front Aging Neurosci"},{"key":"864_CR109","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/brainsci10020093","volume":"10","author":"DE Kim","year":"2020","unstructured":"Kim DE, Priefer R. Therapeutic potential of direct clearance of the amyloid- \u03b2 in Alzheimer\u2019s Disease. Brain Sci. 2020;10:93.","journal-title":"Brain Sci"},{"issue":"7659","key":"864_CR110","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature22809","volume":"546","author":"J Sevigny","year":"2017","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. Addendum: the antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2017;546(7659):564.","journal-title":"Nature"},{"key":"864_CR111","unstructured":"Alzforum. aducanumab still needs to prove itself, researchers say. 2020. https:\/\/www.alzforum.org\/news\/research-news\/aducanumab-still-needs-prove-itself-researchers-say."},{"issue":"7","key":"864_CR112","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.nrl.2014.02.003","volume":"31","author":"M Boada","year":"2016","unstructured":"Boada M, Ramos-Fern\u00e1ndez E, Guivernau B, Mu\u00f1oz F, Costa M, Ortiz A, et al. Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study. Neurologia. 2016;31(7):473\u201381.","journal-title":"Neurologia"},{"key":"864_CR113","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trci.2019.01.001","volume":"5","author":"M Boada","year":"2019","unstructured":"Boada M, L\u00f3pez O, N\u00fa\u00f1ez L, Szczepiorkowski ZM, Torres M, Grifols C, et al. Plasma exchange for Alzheimer\u2019s disease Management by Albumin Replacement (AMBAR) trial: study design and progress. Alzheimers Dement (N Y). 2019;5:61\u20139.","journal-title":"Alzheimers Dement (N Y)"},{"key":"864_CR114","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/alz.12137","volume":"16","author":"M Boada","year":"2020","unstructured":"Boada M, L\u00f3pez OL, Olazar\u00e1n J, N\u00fa\u00f1ez L, Pfeffer M, Paricio M, et al. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer\u2019s disease: primary results of the AMBAR Study. Alzheimer\u2019s Dement. 2020;16:1412\u201325.","journal-title":"Alzheimer\u2019s Dement"},{"key":"864_CR115","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s10571-017-0574-1","volume":"38","author":"FP Chong","year":"2018","unstructured":"Chong FP, Ng KY, Koh RY, Moi CS. Tau proteins and tauopathies in Alzheimer\u2019s Disease. Cell Mol Neurobiol Vol. 2018;38:965\u201380.","journal-title":"Cell Mol Neurobiol Vol"},{"issue":"4","key":"864_CR116","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/JAD-160612","volume":"57","author":"R Rajmohan","year":"2018","unstructured":"Rajmohan R, Reddy PH. Amyloid beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer\u2019s Disease neurons. J Alzheimers Dis. 2018;57(4):975\u201399.","journal-title":"J Alzheimers Dis"},{"key":"864_CR117","first-page":"578373","volume":"2012","author":"J Avila","year":"2012","unstructured":"Avila J, Le\u00f3n-Espinosa G, Garc\u00eda E, Garc\u00eda-Escudero V, Hern\u00e1ndez F, DeFelipe J. Tau phosphorylation by GSK3 in different conditions. Int J Alzheimer\u2019s Dis. 2012;2012:578373.","journal-title":"Int J Alzheimer\u2019s Dis"},{"key":"864_CR118","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam M, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain. 2018;141:1917\u201333.","journal-title":"Brain"},{"issue":"1\u20132","key":"864_CR119","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0006-8993(96)01031-1","volume":"742","author":"Z Pittel","year":"1996","unstructured":"Pittel Z, Heldman E, Barg J, Haring R, Fisher A. Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Brain Res. 1996;742(1\u20132):299\u2013304.","journal-title":"Brain Res"},{"issue":"8","key":"864_CR120","first-page":"471","volume":"42","author":"L Gand\u00eda","year":"2006","unstructured":"Gand\u00eda L, \u00c1lvarez R, De Pascual R, Rojo J, Tapia L. Anticholinesterases in the treatment of Alzheimer\u2019s disease. Rev Neurol. 2006;42(8):471\u20137.","journal-title":"Rev Neurol"},{"key":"864_CR121","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3389\/fnins.2019.01309","volume":"13","author":"J L\u00f3pez-\u00c1lvarez","year":"2019","unstructured":"L\u00f3pez-\u00c1lvarez J, Sevilla-Llewellyn-Jones J, Ag\u00fcera-Ortiz L. Anticholinergic drugs in geriatric psychopharmacology. Front Neurosci. 2019;13:1309.","journal-title":"Front Neurosci"},{"issue":"3","key":"864_CR122","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1460-9568.2006.04957.x","volume":"24","author":"M Suzuki","year":"2006","unstructured":"Suzuki M, Nelson A, Eickstaedt J, Wallace K, Wright L, Svendsen CN. Glutamate enhances proliferation and neurogenesis in human neural progenitor cell cultures derived from the fetal cortex. Eur J Neurosci. 2006;24(3):645\u201353.","journal-title":"Eur J Neurosci"},{"issue":"2","key":"864_CR123","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1476-5381.2012.02057.x","volume":"167","author":"W Danysz","year":"2012","unstructured":"Danysz W, Parsons C. Alzheimer\u2019s disease, \u03b2-amyloid, glutamate, NMDA receptors and memantine-searching for the connections. Br J Pharmacol. 2012;167(2):324\u201352.","journal-title":"Br J Pharmacol"},{"key":"864_CR124","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3892\/br.2016.630","volume":"4","author":"WJ Huang","year":"2016","unstructured":"Huang WJ, Zhang X, Chen W. Role of oxidative stress in Alzheimer\u2019s disease. Biomed Rep. 2016;4:519\u201322.","journal-title":"Biomed Rep"},{"issue":"8","key":"864_CR125","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/jnen\/60.8.759","volume":"60","author":"A Nunomura","year":"2009","unstructured":"Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2009;60(8):759\u201367.","journal-title":"J Neuropathol Exp Neurol"},{"key":"864_CR126","doi-asserted-by":"crossref","unstructured":"Essa MM, Akbar M, Gilles G. The benefits of natural products for neurodegenerative diseases. 2016. pp. 107\u2013123.","DOI":"10.1007\/978-3-319-28383-8_7"},{"key":"864_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2019.00233","volume":"11","author":"A Hemonnot","year":"2019","unstructured":"Hemonnot A, Hua J, Ulmann L, Hirbec H. Microglia in Alzheimer Disease: well-known targets and new opportunities. Front Aging Neurosci. 2019;11:1\u201320.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"864_CR128","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1474-4422(18)30490-3","volume":"18","author":"AM Arranz","year":"2019","unstructured":"Arranz AM, De SB. The role of astroglia in Alzheimer\u2019s disease: pathophysiology and clinical implications. Lancet Neurol. 2019;18(4):406\u201314.","journal-title":"Lancet Neurol"},{"key":"864_CR129","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/JIR.S86958","volume":"9","author":"M Bronzuoli","year":"2016","unstructured":"Bronzuoli M, Iacomino A, Steardo L, Scuderi C. Targeting neuroinflammation in Alzheimer\u2019s disease. J Inflamm Res. 2016;9:199\u2013208.","journal-title":"J Inflamm Res"},{"issue":"5","key":"864_CR130","first-page":"e4620","volume":"11","author":"MM Ali","year":"2019","unstructured":"Ali MM, Ghouri RG, Ans AH, Akbar A, Toheed A. Recommendations for anti-inflammatory treatments in Alzheimer\u2019s Disease: a comprehensive review of the literature. Cureus. 2019;11(5):e4620.","journal-title":"Cureus"},{"issue":"2","key":"864_CR131","doi-asserted-by":"publisher","first-page":"201","DOI":"10.14336\/AD.2015.1007","volume":"7","author":"IG Onyango","year":"2016","unstructured":"Onyango IG, Dennis J, Khan SM, Biotechnology G, St BF. Mitochondrial dysfunction in Alzheimer\u2019s Disease and the rationale for bioenergetics based therapies. Aging Dis. 2016;7(2):201\u201314.","journal-title":"Aging Dis"},{"key":"864_CR132","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","volume":"76","author":"R Anand","year":"2014","unstructured":"Anand R, Gill K, Mahdi A. Therapeutics of Alzheimer\u2019s disease: past, present and future. Neuropharmacology. 2014;76:27\u201350.","journal-title":"Neuropharmacology"},{"key":"864_CR133","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.addr.2008.04.015","volume":"60","author":"A Maczurek","year":"2008","unstructured":"Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, et al. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer\u2019s disease. Adv Drug Deliv Rev. 2008;60:1463\u201370.","journal-title":"Adv Drug Deliv Rev"},{"key":"864_CR134","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1749-6632.2001.tb03654.x","volume":"939","author":"S Bachurin","year":"2001","unstructured":"Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci. 2001;939:425\u201335.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"864_CR135","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5483\/BMBRep.2020.53.1.279","volume":"53","author":"J Woong Lim","year":"2020","unstructured":"Woong Lim J, Lee J, Pae N. Mitochondrial dysfunction and Alzheimer\u2019s disease: prospects for therapeutic intervention. BMB Rep. 2020;53(1):47\u201355.","journal-title":"BMB Rep"},{"issue":"3","key":"864_CR136","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/archneurol.2009.27","volume":"66","author":"S Craft","year":"2009","unstructured":"Craft S. The role of metabolic disorders in Alzheimer\u2019s Disease and vascular dementia: two roads converged? Arch Neurol. 2009;66(3):300\u20135.","journal-title":"Arch Neurol"},{"key":"864_CR137","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1038\/s41598-018-24248-8","volume":"8","author":"C-S Chu","year":"2018","unstructured":"Chu C-S, Tseng P-T, Stubbs B, Chen T-Y, Tang C-H, Li D-J, et al. Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. 2018;8:5804.","journal-title":"Sci Rep"},{"issue":"1","key":"864_CR138","doi-asserted-by":"publisher","first-page":"83","DOI":"10.31887\/DCNS.2019.21.1\/bbendlin","volume":"21","author":"BB Bendlin","year":"2019","unstructured":"Bendlin BB. Antidiabetic therapies and Alzheimer disease. Dialogues Clin Neurosci. 2019;21(1):83\u201391.","journal-title":"Dialogues Clin Neurosci"},{"key":"864_CR139","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jconrel.2015.10.005","volume":"219","author":"YH Yun","year":"2015","unstructured":"Yun YH, Lee BK, Park K, Lafayette W. Controlled drug delivery: historical perspective for the next generation. J Control Release. 2015;219:2\u20137.","journal-title":"J Control Release"},{"issue":"3","key":"864_CR140","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s11705-014-1426-x","volume":"8","author":"Y Yun","year":"2014","unstructured":"Yun Y, Lee B, Park K. Controlled drug delivery systems: the next 30 years. Front Chem Sci Eng. 2014;8(3):276\u20139.","journal-title":"Front Chem Sci Eng"},{"key":"864_CR141","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s11164-013-1338-2","volume":"41","author":"F Bassyouni","year":"2015","unstructured":"Bassyouni F, Elhalwany N. Advances and new technologies applied in controlled drug delivery system. Res Chem Intermed. 2015;41:2165\u2013200.","journal-title":"Res Chem Intermed"},{"key":"864_CR142","doi-asserted-by":"publisher","unstructured":"Benoit DSW, Overby CT, Jr KRS, Ackun-farmmer MA. 2.5.12 - Drug Delivery Systems. Fourth Edi. Biomaterials Science. Elsevier Inc.; 2020. pp. 1237\u20131259.e3. https:\/\/doi.org\/10.1016\/B978-0-12-816137-1.00079-9","DOI":"10.1016\/B978-0-12-816137-1.00079-9"},{"key":"864_CR143","doi-asserted-by":"publisher","first-page":"102149","DOI":"10.1016\/j.nano.2020.102149","volume":"24","author":"H Derakhshankhah","year":"2020","unstructured":"Derakhshankhah H, Sajadimajd S, Jafari S, Izadi Z, Sarvari S, Sharifi M, et al. Novel therapeutic strategies for Alzheimer\u2019s disease: implications from cell-based therapy and nanotherapy. Nanomed Nanotechnol Biol Med. 2020;24:102149.","journal-title":"Nanomed Nanotechnol Biol Med."},{"issue":"4","key":"864_CR144","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1021\/cn3002015","volume":"4","author":"H Kouyoumdjian","year":"2013","unstructured":"Kouyoumdjian H, Zhu DC, El-Dakdouki MH, Lorenz K, Chen J, Li W, et al. Glyconanoparticle aided detection of \u03b2-Amyloid by Magnetic resonance imaging and attenuation of \u03b2-Amyloid Induced Cytotoxicity. ACS Chem Neurosci. 2013;4(4):575\u201384.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"864_CR145","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nnano.2014.254","volume":"10","author":"KL Viola","year":"2015","unstructured":"Viola KL, Sbarboro J, Sureka R, De M, Bicca MA, Wang J, et al. Towards non-invasive diagnostic imaging of early-stage Alzheimer\u2019s disease. Nat Nanotechnol. 2015;10(1):91\u20138.","journal-title":"Nat Nanotechnol"},{"issue":"2","key":"864_CR146","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3233\/JAD-151124","volume":"52","author":"EA Tanifum","year":"2016","unstructured":"Tanifum EA, Ghaghada K, Vollert C, Head E, Eriksen JL, Annapragada A. A novel liposomal nanoparticle for the imaging of amyloid plaque by magnetic resonance imaging. J Alzheimers Dis. 2016;52(2):731\u201345.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"864_CR147","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jsps.2012.03.005","volume":"20","author":"YN Gavhanea","year":"2012","unstructured":"Gavhanea YN, Yadav AV. Loss of orally administered drugs in GI tract. Saudi Pharm J. 2012;20(4):331\u201344.","journal-title":"Saudi Pharm J"},{"key":"864_CR148","doi-asserted-by":"publisher","first-page":"484963","DOI":"10.1155\/2015\/484963","volume":"2015","author":"FG Hoosain","year":"2015","unstructured":"Hoosain FG, Choonara YE, Tomar LK, Kumar P, Tyagi C, du Toit LC, et al. Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy. Biomed Res Int. 2015;2015:484963.","journal-title":"Biomed Res Int"},{"issue":"3","key":"864_CR149","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1211\/0022357055263","volume":"57","author":"H Lennern\u00e4s","year":"2005","unstructured":"Lennern\u00e4s H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol. 2005;57(3):273\u201385.","journal-title":"J Pharm Pharmacol"},{"issue":"12","key":"864_CR150","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2217\/nnm-2019-0443","volume":"15","author":"A Cano","year":"2020","unstructured":"Cano A, S\u00e1nchez-L\u00f3pez E, Ettcheto M, L\u00f3pez-Machado A, Espina M, Souto EB, et al. Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. Nanomedicine (London). 2020;15(12):1239\u201361.","journal-title":"Nanomedicine (London)"},{"key":"864_CR151","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","volume":"29","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood M. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29:341\u20135.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"864_CR152","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3109\/09687688.2014.937468","volume":"31","author":"M Tajes","year":"2014","unstructured":"Tajes M, Ramos-fern\u00e1ndez E, Weng-jiang X, Bosch-morat\u00f3 M, Guivernau B, Eraso-pichot A, et al. The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol Membr Biol. 2014;31(5):152\u201367.","journal-title":"Mol Membr Biol"},{"key":"864_CR153","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejpb.2018.10.017","volume":"133","author":"A Gordillo-galeano","year":"2018","unstructured":"Gordillo-galeano A, Mora-huertas CE. Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release. Eur J Pharm Biopharm. 2018;133:285\u2013308.","journal-title":"Eur J Pharm Biopharm"},{"issue":"12","key":"864_CR154","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2174\/1381612826666200116142922","volume":"26","author":"A Cano","year":"2020","unstructured":"Cano A, Espina M, Garc\u00eda M. Recent advances on anti-tumor agents-loaded polymeric and lipid based nano-carriers for the treatment of brain cancer. Curr Pharm Des. 2020;26(12):1316\u201330.","journal-title":"Curr Pharm Des"},{"key":"864_CR155","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.onano.2017.12.001","volume":"3","author":"V Campani","year":"2018","unstructured":"Campani V, Giarra S, De RG. Lipid-based core-shell nanoparticles: evolution and potentialities in drug delivery. OpenNano. 2018;3:5\u201317.","journal-title":"OpenNano"},{"issue":"1","key":"864_CR156","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jps.23773","volume":"103","author":"J Kraft","year":"2014","unstructured":"Kraft J, Freeling J, Wang Z, Ho R. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci. 2014;103(1):29\u201352.","journal-title":"J Pharm Sci"},{"issue":"7","key":"864_CR157","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.sjbs.2020.04.045","volume":"27","author":"MS Almuhayawi","year":"2020","unstructured":"Almuhayawi MS, Ramadan WS, Harakeh S, Al SK, Bharali DJ, Mousa SA, et al. The potential role of pomegranate and its nano-formulations on cerebral neurons in aluminum chloride induced Alzheimer rat model. Saudi J Biol Sci. 2020;27(7):1710\u20136.","journal-title":"Saudi J Biol Sci"},{"key":"864_CR158","doi-asserted-by":"publisher","first-page":"146325","DOI":"10.1016\/j.brainres.2019.146325","volume":"1721","author":"R Giacomeli","year":"2019","unstructured":"Giacomeli R, Cristina J, Bem R, Peterini S, Ricardo C, Elisa S. Neuroprotective effects of curcumin lipid-core nanocapsules in a model Alzheimer\u2019s disease induced by \u03b2-amyloid 1\u201342 peptide in aged female mice. Brain Res. 2019;1721:146325.","journal-title":"Brain Res"},{"issue":"1","key":"864_CR159","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1208\/s12248-012-9432-8","volume":"15","author":"SC Gupta","year":"2013","unstructured":"Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195\u2013218.","journal-title":"AAPS J"},{"key":"864_CR160","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/d41573-020-00102-3","volume":"19","author":"J Willson","year":"2020","unstructured":"Willson J. Transferrin\u2019 across the blood\u2013brain barrier. Nat Rev Drug Discov. 2020;19:444.","journal-title":"Nat Rev Drug Discov"},{"key":"864_CR161","doi-asserted-by":"publisher","first-page":"105314","DOI":"10.1016\/j.ejps.2020.105314","volume":"148","author":"RGR Pinheiro","year":"2020","unstructured":"Pinheiro RGR, Granja A, Loureiro JA, Pereira MC, Pinheiro M, Neves AR, et al. Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer`s disease. Eur J Pharm Sci. 2020;148:105314.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"864_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11746-009-1483-3","volume":"87","author":"GPP Kamatou","year":"2010","unstructured":"Kamatou GPP, Viljoen AM. A review of the application and pharmacological properties of \u03b1-Bisabolol and \u03b1-Bisabolol-rich oils. JAOCS. 2010;87(1):1\u20137.","journal-title":"JAOCS"},{"key":"864_CR163","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.molliq.2018.05.075","volume":"264","author":"S Sathya","year":"2018","unstructured":"Sathya S, Shanmuganathan B, Manirathinam G, Ruckmani K, Pandima K. \u03b1 -Bisabolol loaded solid lipid nanoparticles attenuates A \u03b2 aggregation and protects Neuro-2a cells from A \u03b2 induced neurotoxicity. J Mol Liq. 2018;264:431\u201341.","journal-title":"J Mol Liq"},{"key":"864_CR164","doi-asserted-by":"publisher","first-page":"110948","DOI":"10.1016\/j.colsurfb.2020.110948","volume":"190","author":"S Sathya","year":"2020","unstructured":"Sathya S, Shanmuganathan B, Devi KP. Deciphering the anti-apoptotic potential of \u03b1 -bisabolol loaded solid lipid nanoparticles against A \u03b2 induced neurotoxicity in Neuro-2a cells. Colloids Surf B. 2020;190:110948.","journal-title":"Colloids Surf B"},{"key":"864_CR165","doi-asserted-by":"publisher","first-page":"107082","DOI":"10.1016\/j.nlm.2019.107082","volume":"166","author":"T Dara","year":"2019","unstructured":"Dara T, Vatanara A, Sharifzadeh M, Khani S. Improvement of memory deficits in the rat model of Alzheimer`s disease by erythropoietin-loaded solid lipid nanoparticles. Neurobiol Learn Mem. 2019;166:107082.","journal-title":"Neurobiol Learn Mem"},{"issue":"10","key":"864_CR166","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2174\/156802661510150328224527","volume":"15","author":"J Punnonen","year":"2015","unstructured":"Punnonen J, Miller JL, Collier TJ, Spencer JR. Agonists of the tissue-protective erythropoietin receptor in the treatment of Parkinson\u2019s disease. Curr Top Med Chem. 2015;15(10):955\u201369.","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"864_CR167","doi-asserted-by":"publisher","first-page":"23","DOI":"10.17219\/acem\/61044","volume":"26","author":"B Cevik","year":"2017","unstructured":"Cevik B, Solmaz V, Yigitturk G, Cavuso\u011flu T, Gonul P, Erbas O. Neuroprotective effects of erythropoietin on Alzheimer\u2019s dementia model in rats. Adv Clin Exp Med. 2017;26(1):23\u20139.","journal-title":"Adv Clin Exp Med"},{"key":"864_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","volume":"75","author":"A Kumari","year":"2010","unstructured":"Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B. 2010;75:1\u201318.","journal-title":"Colloids Surf B"},{"key":"864_CR169","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.nano.2005.12.003","volume":"2","author":"CP Reis","year":"2006","unstructured":"Reis CP, Neufeld RJ. Nanoencapsulation. I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomed Nanotechnol Biol Med. 2006;2:8\u201321.","journal-title":"Nanomed Nanotechnol Biol Med."},{"issue":"1\u20132","key":"864_CR170","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ijpharm.2017.06.052","volume":"528","author":"KM El-say","year":"2017","unstructured":"El-say KM, El-sawy HS. Polymeric nanoparticles: Promising platform for drug delivery. Int J Pharm. 2017;528(1\u20132):675\u201391.","journal-title":"Int J Pharm"},{"key":"864_CR171","doi-asserted-by":"publisher","first-page":"495602","DOI":"10.1088\/0957-4484\/26\/49\/495602","volume":"26","author":"S Liu","year":"2015","unstructured":"Liu S, Qiao S, Li L, Qi G, Lin Y. Surface charge-conversion polymeric nanoparticles for photodynamic treatment of urinary tract bacterial infections. Nanotechnology. 2015;26:495602.","journal-title":"Nanotechnology"},{"issue":"3","key":"864_CR172","first-page":"16","volume":"5","author":"BVN Nagavarma","year":"2012","unstructured":"Nagavarma BVN, Yadav HKS, Ayaz A, Vasudha LS, Shivakumar HG. Different techniques for preparation of polymeric nanoparticles-a review. Asian J Pharm Clin Res. 2012;5(3):16\u201323.","journal-title":"Asian J Pharm Clin Res"},{"key":"864_CR173","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ijpharm.2008.04.042","volume":"364","author":"C Wischke","year":"2008","unstructured":"Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA \/ PLGA microparticles. Int J Pharm. 2008;364:298\u2013327.","journal-title":"Int J Pharm"},{"key":"864_CR174","doi-asserted-by":"publisher","first-page":"119553","DOI":"10.1016\/j.ijpharm.2020.119553","volume":"586","author":"N Dhas","year":"2020","unstructured":"Dhas N, Mehta T. Cationic biopolymer functionalized nanoparticles encapsulating lutein to attenuate oxidative stress in effective treatment of Alzheimer\u2019s disease: a non-invasive approach. Int J Pharm. 2020;586:119553.","journal-title":"Int J Pharm"},{"issue":"4","key":"864_CR175","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/molecules22040610","volume":"22","author":"Y-P Jia","year":"2017","unstructured":"Jia Y-P, Sun L, Yu H-S, Liang L-P, Li W, Ding H, et al. The Pharmacological effects of lutein and zeaxanthin on visual disorders and cognition diseases. Molecules. 2017;22(4):610.","journal-title":"Molecules"},{"key":"864_CR176","doi-asserted-by":"publisher","first-page":"110962","DOI":"10.1016\/j.fct.2019.110962","volume":"136","author":"S Sathya","year":"2020","unstructured":"Sathya S, Shanmuganathan B, Balasubramaniam B, Balamurugan K, Devi KP. Phytol loaded PLGA nanoparticles regulate the expression of Alzheimer\u2019s related genes and neuronal apoptosis against amyloid- \u03b2 induced toxicity in Neuro-2a cells and transgenic Caenorhabditis elegans. Food Chem Toxicol. 2020;136:110962.","journal-title":"Food Chem Toxicol"},{"key":"864_CR177","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.fct.2018.08.032","volume":"121","author":"MT Islam","year":"2019","unstructured":"Islam MT, Ali ES, Uddin SJ, Shaw S, Islam MA, Ahmed MI, et al. Phytol: a review of biomedical activities. Food Chem Toxicol. 2019;121:82\u201394.","journal-title":"Food Chem Toxicol"},{"key":"864_CR178","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jconrel.2019.03.010","volume":"301","author":"A Cano","year":"2019","unstructured":"Cano A, Ettcheto M, Chang J, Barroso E, Espina M, K\u00fchne B, et al. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate ( EGCG )\/ Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe \/ PS1dE9 Alzheimer\u2019 s disease mice model. J Control Release. 2019;301:62\u201375.","journal-title":"J Control Release"},{"key":"864_CR179","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.biopha.2015.12.013","volume":"78","author":"A Chowdhury","year":"2016","unstructured":"Chowdhury A, Sarkar J, Chakraborti T, Pramanik PK, Chakraborti S. Protective role of epigallocatechin-3-gallate in health and disease: a perspective. Biomed Pharmacother. 2016;78:50\u20139.","journal-title":"Biomed Pharmacother"},{"key":"864_CR180","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.nano.2018.09.010","volume":"16","author":"KM Ahlschwede","year":"2019","unstructured":"Ahlschwede KM, Curran GL, Rosenberg JT, Grant SC, Sarkar G, Jenkins RB, et al. Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer\u2019 s disease brain. Nanomed Nanotechnol Biol Med. 2019;16:258\u201366.","journal-title":"Nanomed Nanotechnol Biol Med."},{"key":"864_CR181","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.aca.2020.01.021","volume":"1105","author":"C Liu","year":"2020","unstructured":"Liu C, Lu D, You X, Shi G, Deng J. Carbon dots sensitized lanthanide infinite coordination polymer nanoparticles: towards ratiometric fluorescent sensing of cerebrospinal A\u03b2 monomer as a biomarker for Alzheimer\u2019s disease. Anal Chim Acta. 2020;1105:147\u201354.","journal-title":"Anal Chim Acta"},{"key":"864_CR182","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.nano.2019.02.004","volume":"17","author":"SG Jeon","year":"2019","unstructured":"Jeon SG, Cha M, Kim J, Hwang TW, Kim KA, Kim TH, et al. Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer\u2019 s disease-related pathology in 5XFAD mice. Nanomed Nanotechnol Biol Med. 2019;17:297\u2013307.","journal-title":"Nanomed Nanotechnol Biol Med."},{"issue":"4","key":"864_CR183","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1309\/W01Y0B808EMEH12L","volume":"129","author":"J Zhang","year":"2008","unstructured":"Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129(4):526\u20139.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"864_CR184","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3233\/JAD-140042","volume":"43","author":"RJ Bishnoi","year":"2015","unstructured":"Bishnoi RJ, Palmer RF, Royall DR. Vitamin D binding protein as a serum biomarker of Alzheimer\u2019s disease. J Alzheimers Dis. 2015;43(1):37\u201345.","journal-title":"J Alzheimers Dis"},{"key":"864_CR185","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jconrel.2020.01.039","volume":"320","author":"Q Guo","year":"2020","unstructured":"Guo Q, Xu S, Yang P, Wang P, Lu S, Sheng D, et al. A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer\u2019s disease mice. J Control Release. 2020;320:347\u201362.","journal-title":"J Control Release"},{"key":"864_CR186","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.3390\/ijms19124031","volume":"19","author":"B Klebowski","year":"2018","unstructured":"Klebowski B, Depciuch J, Parlinska-Wojtan M, Baran J. Applications of noble metal-based nanoparticles in medicine. Int J Mol Sci. 2018;19:4031.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"864_CR187","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/nano10020292","volume":"10","author":"E S\u00e1nchez-l\u00f3pez","year":"2020","unstructured":"S\u00e1nchez-l\u00f3pez E, Gomes D, Esteruelas G, Bonilla L, Lopez-machado AL, Galindo R, et al. Metal-based nanoparticles as antimicrobial agents: an overview. Nanomaterials. 2020;10(2):292.","journal-title":"Nanomaterials"},{"key":"864_CR188","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jphotobiol.2017.05.034","volume":"173","author":"ZUH Khan","year":"2017","unstructured":"Khan ZUH, Khan A, Chen Y, Shah NS, Muhammad N, Khan AU, et al. Biomedical applications of green synthesized Nobel metal nanoparticles. J Photochem Photobiol B. 2017;173:150\u201364.","journal-title":"J Photochem Photobiol B"},{"key":"864_CR189","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.jddst.2019.101174","volume":"53","author":"P Govindrao","year":"2019","unstructured":"Govindrao P, Ghule NW, Haque A, Kalaskar MG. Metal nanoparticles synthesis: an overview on methods of preparation, advantages and disadvantages, and applications. J Drug Deliv Sci Technol. 2019;53:101174.","journal-title":"J Drug Deliv Sci Technol"},{"key":"864_CR190","doi-asserted-by":"crossref","unstructured":"Rana A, Yadav K, Jagadevan S. A comprehensive review on green synthesis of nature-inspired metal nanoparticles: Mechanism, application and toxicity. J Cleaner Prod. 2020;122880.","DOI":"10.1016\/j.jclepro.2020.122880"},{"issue":"50","key":"864_CR191","doi-asserted-by":"publisher","first-page":"502003","DOI":"10.1088\/1361-6528\/ab4241","volume":"30","author":"K Wu","year":"2019","unstructured":"Wu K, Su D, Liu J, Saha R, Wang J-P. Magnetic nanoparticles in nanomedicine: a review of recent advances. Nanotechnology. 2019;30(50):502003.","journal-title":"Nanotechnology"},{"key":"864_CR192","doi-asserted-by":"publisher","first-page":"114050","DOI":"10.1016\/j.jelechem.2020.114050","volume":"872","author":"W da Silva","year":"2020","unstructured":"da Silva W, Brett CMA. Novel biosensor for acetylcholine based on acetylcholinesterase \/ poly (neutral red)\u2014deep eutectic solvent \/ Fe2O3 nanoparticle modified electrode. J Electroanal Chem. 2020;872:114050.","journal-title":"J Electroanal Chem."},{"key":"864_CR193","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.2147\/IJN.S132776","volume":"12","author":"Y Xing","year":"2017","unstructured":"Xing Y, Feng X-Z, Zhang L, Hou J, Han G-C, Chen Z. A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles. Int J Nanomed. 2017;12:3171\u20139.","journal-title":"Int J Nanomed"},{"key":"864_CR194","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jcis.2019.05.066","volume":"552","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhou H, Yin T, Gong Y, Yuan G, Chen L, et al. Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer\u2019 s disease. J Colloid Interf Sci. 2019;552:388\u2013400.","journal-title":"J Colloid Interf Sci"},{"key":"864_CR195","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ijbiomac.2019.09.098","volume":"142","author":"F Gao","year":"2020","unstructured":"Gao F, Zhao J, Liu P, Ji D, Zhang L, Zhang M, et al. Preparation and in vitro evaluation of multi-target-directed selenium- chondroitin sulfate nanoparticles in protecting against the Alzheimer \u2019 s disease. Int J Biol Macromol. 2020;142:265\u201376.","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"864_CR196","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.biocel.2012.01.004","volume":"44","author":"JCF Kwok","year":"2012","unstructured":"Kwok JCF, Warren P, Fawcett JW. Chondroitin sulfate: a key molecule in the brain matrix. Int J Biochem Cell Biol. 2012;44(4):582\u20136.","journal-title":"Int J Biochem Cell Biol"},{"key":"864_CR197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinorgbio.2015.09.003","volume":"153","author":"ND Solovyev","year":"2015","unstructured":"Solovyev ND. Importance of selenium and selenoprotein for brain function: from antioxidant protection to neuronal signalling. J Inorg Biochem. 2015;153:1\u201312.","journal-title":"J Inorg Biochem"},{"key":"864_CR198","doi-asserted-by":"publisher","first-page":"12833","DOI":"10.1021\/acsomega.9b01411","volume":"4","author":"SK Sonawane","year":"2019","unstructured":"Sonawane SK, Ahmad A, Chinnathambi S. Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer\u2019s Disease. ACS Omega. 2019;4:12833\u201340.","journal-title":"ACS Omega"},{"key":"864_CR199","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.actbio.2016.09.010","volume":"46","author":"L Yang","year":"2016","unstructured":"Yang L, Yin T, Liu Y, Sun J, Zhou Y, Liu J. Gold nanoparticle-capped mesoporous silica-based H2O2 -responsive controlled release system for Alzheimer`s disease treatment. Acta Biomater. 2016;46:177\u201390.","journal-title":"Acta Biomater"},{"key":"864_CR200","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.biomaterials.2019.01.037","volume":"197","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhao P, Yue C, Jin Z, Liu Q, Du X, et al. Sustained release of bioactive hydrogen by Pd hydride nanoparticles overcomes Alzheimer\u2019s disease. Biomaterials. 2019;197:393\u2013404.","journal-title":"Biomaterials"},{"key":"864_CR201","doi-asserted-by":"publisher","first-page":"107968","DOI":"10.1016\/j.dyepig.2019.107968","volume":"173","author":"J Cai","year":"2020","unstructured":"Cai J, Dao P, Chen H, Yan L, Liang Y, Zhang W, et al. Ultrasmall superparamagnetic iron oxide nanoparticles-bound NIR dyes: novel theranostic agents for Alzheimer\u2019s disease. Dyes Pigm. 2020;173:107968.","journal-title":"Dyes Pigm"},{"key":"864_CR202","doi-asserted-by":"publisher","first-page":"104755","DOI":"10.1016\/j.neuint.2020.104755","volume":"138","author":"T Wahle","year":"2020","unstructured":"Wahle T, Sofranko A, Dekkers S, Miller MR, Heusinkveld HJ, Albrecht C, et al. Evaluation of neurological effects of cerium dioxide nanoparticles doped with different amounts of zirconium following inhalation exposure in mouse models of Alzheimer \u2019s and vascular disease. Neurochem Int. 2020;138:104755.","journal-title":"Neurochem Int"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-021-00864-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-021-00864-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-021-00864-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T23:53:02Z","timestamp":1698969182000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-021-00864-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":202,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1186\/s12951-021-00864-x","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The corresponding author of this manuscript, Dr. Amanda Cano, on behalf of all co-authors (Patric Turowski, Miren Ettcheto, Jason Thomas Duskey, Giovanni Tosi, Elena S\u00e1nchez-L\u00f3pez, Maria Luisa Garc\u00eda, Antonio Camins, Eliana B. Souto, Agust\u00edn Ruiz, Marta Marqui\u00e9 and Merc\u00e8 Boada) declares the consent of publication of this manuscript in the <i>Journal of Nanobiotechnology<\/i>. All authors have read and approved the submitted final version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors has any conflicts of interest including any financial, personal or other relationships with other people or organizations. All authors have reviewed the contents of the manuscript being submitted and approved its contents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}